OK Biotech Co (4155) Fair Value & Analysis
Healthcare · TW · Market cap 2.1B TWD
Fair value as of: Jun 24, 2026
Analysis
OK Biotech Co (4155) currently trades at 15.00 TWD, while our model-based Fair Value estimate is 12.86 TWD — implying the stock looks roughly 14.3% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe. The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips. It also provides OTC hearing aids, multi-frequency therapy devices, and factory setup solutions, as well as professional OEM/ODM customized services. The company sells its products under the OKB and Prodigy brands. OK Biotech Co., Ltd. was incorporated in 2004 and is headquartered in Hsinchu City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is OK Biotech Co (4155) undervalued?
What is the fair value of 4155?
What is the quality score of 4155?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.